PI3K inhib 
Welcome,         Profile    Billing    Logout  
 67 Companies  59 Products   59 Products   344 Diseases   343 Trials   12261 News 


«12...207208209210211212213214215216217...229230»
  • ||||||||||  Journal:  Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway. (Pubmed Central) -  Aug 1, 2019   
    Mechanistically, we detected detectable reductions of apoptosis related proteins, (epithelial-mesenchymal transition) EMT related proteins and activity of phosphatidylinositol 3-kinase(PI3K)/Akt/ mammalian target of rapamycin (mTOR) signaling in U2OS and MG-63 cells exposure to MDA19. Overall, the current study indicates in vitro anti-proliferative, anti-metastatic and pro-apoptotic potential of MDA19 in U2OS and MG-63 cells.
  • ||||||||||  Biomarker, Journal:  LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway. (Pubmed Central) -  Aug 1, 2019   
    Moreover, the activation of this pathway could rescue the inhibitory effects of TP73-AS1 suppression on LAD cellular processes in partial. These data suggested that TP73-AS1 served as an oncogene in LAD partially through activating PI3K/AKT pathway and it could be a potential target for diagnosis and treatment of LAD.
  • ||||||||||  quercetin (LY294002) / Eli Lilly
    Journal:  Alpha-enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway. (Pubmed Central) -  Aug 1, 2019   
    ENO1 could modulate AKT signaling pathway in GC cells and the enhanced proliferation and migration ability induced by ENO1 overexpression was impaired after incubation with PI3K inhibitor Ly294002 in SGC7901 cells. Our data demonstrated that ENO1 enhances GC cell proliferation and metastasis through the protein kinase B (AKT) signaling pathway, indicating that ENO1/AKT signaling axis may serve as a potential target for treatment of GC.
  • ||||||||||  pictilisib (GDC-0941) / Roche
    Journal, PD(L)-1 Biomarker, IO Biomarker:  PCC0208018 exerts antitumor effects by activating effector T cells. (Pubmed Central) -  Aug 1, 2019   
    In B16-F10 melanoma-harboring mice, PCC0208018 significantly inhibited tumor growth as well as increasing CD3, CD3CD4, and CD3CD8 T cell abundance in tumors without affecting PD-L1 expression. This study showed that PCC0208018 potentially increased PBMCs proliferation and function by activating the phosphatidylinositol 3 kinase (PI3K)/AKT and mitogen-activated protein kinase (MEK)/ERK pathways to exert antitumor effects.
  • ||||||||||  Aliqopa (copanlisib) / Bayer
    Trial completion date, Trial primary completion date:  Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients (clinicaltrials.gov) -  Jul 29, 2019   
    P1/2,  N=130, Recruiting, 
    Our results demonstrated that BP protected HUVECs against oxidative damage partly via PI3K/Akt/mTOR-mediated Nrf/HO-1 pathway, which might be applied into preventing Ox-LDL mediated cardiovascular diseases. Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Apr 2022 --> Jan 2023
  • ||||||||||  Journal, PARP Biomarker:  miR-125 regulates PI3K/Akt/mTOR signaling pathway in rheumatoid arthritis rats via PARP2. (Pubmed Central) -  Jul 26, 2019   
    Compared with NC group, cells of mimics+siPARP2 group had significantly lower IL-1β, MMP-1 and TIMP-1 levels, absorbance value, and p-PI3K, p-Akt and p-mTOR relative expression ( P < 0.01 or P < 0.05). Thus, miR-125 might attenuate RA development by regulating PI3K/Akt/mTOR signaling pathway via directly inhibiting PARP2 expression.
  • ||||||||||  PF-655 / Quark
    Biomarker, Journal:  Elevated RTP801 promotes cell proliferation in non-small cell lung cancer. (Pubmed Central) -  Jul 26, 2019   
    Our results demonstrated that hyperglycemia exacerbated APAP-induced acute liver injury by promoting liver-resident macrophage proinflammatory response via AMPK/PI3K/AKT-mediated oxidative stress. Taken together, our study provides the novel and direct evidence that there is a close relationship between RTP801 and human NSCLC, and RTP801 can promote the proliferation of NSCLC cells which is regulated by PI3K signaling pathway, suggesting that RTP801 could be a potential biomarker for diagnosis and therapeutic target of human NSCLC.
  • ||||||||||  Clinical, Journal:  Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer. (Pubmed Central) -  Jul 25, 2019   
    Combining SNA with anti-PD1 dramatically slowed osteosarcoma tumor growth and prolonged survival time of tumor-bearing mice, at least in part mediated through CD8 T cells. Our results demonstrated that addition of SNA to anti-PD1 significantly altered infiltration and function of innate immune cells, providing the rationale for combination therapy in patients with osteosarcoma through inhibiting the function of MDSCs with a selective PI3Kδ/γ inhibitor to enhance responses to immune checkpoint blockade.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    Preclinical, Journal:  Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells. (Pubmed Central) -  Jul 24, 2019   
    Furthermore, we show that the KPL-4 T-DM1 resistance can be overcome by treatment with an inhibitor of MDR1, whereas a PI3K inhibitor can rescue PTEN loss-induced resistance in T-DM1-resistant BT-474M1 cells. Our results provide a rationale for developing therapeutic strategies to enhance T-DM1 clinical efficacy by combining T-DM1 and other inhibitors that target signaling transduction or resistance pathways.
  • ||||||||||  Biomarker, Journal:  Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. (Pubmed Central) -  Jul 24, 2019   
    Particularly relevant in CRC are the activating mutations in the oncogene PIK3CA that frequently occur in concomitancy with KRAS and BRAF mutations and that lead to deregulation of the major signalling pathways PI3K and MAPK, downstream of EGFR. This review focus on the importance of the PI3K signalling in CRC development, on the current knowledge of PI3K inhibition as a therapeutic approach in CRC and on the implications PI3K signalling molecules may have as potential biomarkers and as new targets for directed therapies in CRC patients.
  • ||||||||||  Journal:  PKA and PI3K activities during capacitation protect sperm from undergoing spontaneous acrosome reaction. (Pubmed Central) -  Jul 24, 2019   
    Inhibition of the PLD pathway resulted in an increase in sAR and a decrease in F-actin levels which can be artificially reversed by inhibition of protein - phosphatase 1 (PP1), and this effect is mediated by PI3K. All together, we showed that PKA via PLD and PI3K activation protects the sperm from undergoing sAR by enhancing actin polymerization.
  • ||||||||||  quercetin (LY294002) / Eli Lilly
    Journal:  Wound Healing Potential of Spirulina Protein on CCD-986sk Cells. (Pubmed Central) -  Jul 24, 2019   
    However, the phosphorylation of Akt was significantly blocked by PI3K inhibitor (LY294002), which in turn reduced the SPCP-induced proliferation and migration of CCD-986sk cells. Therefore, the results presenting in this study suggested that SPCP can promote the proliferation and migration of CCD-986sk cells; the PI3K/Akt signaling pathway play a positive and important role in these processes.